Investors
Baxtra is a privately held company. There is no public stock, no quarterly earnings call, and no revenue from medicines — here is what there is instead.
Financing history
| Round | Date | Amount | Purpose |
|---|---|---|---|
| Series A | March 2025 | $90M | Company formation, Jupiter laboratories, first four discovery programs |
| Series B | March 2026 | $175M | Phase 1 completion across all four medicines; SealWeave design verification; Lumavue commercial launch |
| Total | — | $265M | — |
Where the $90 million went
| Area | R&D spend to date | Share |
|---|---|---|
| Discovery chemistry and biology (four programs) | $31.5M | 35% |
| IND-enabling toxicology and clinical manufacturing | $19.8M | 22% |
| Clinical trial execution | $16.2M | 18% |
| Surgical technology engineering and verification | $14.4M | 16% |
| Laboratory and simulation facilities | $8.1M | 9% |
Figures are cumulative from incorporation in March 2025 through 30 June 2026 and are provided for information only.
What comes next
Phase 1 data readouts across BX-101, BX-204 and BX-412 during 2027; BX-308 IND filing; SealWeave regulatory submission; Lumavue expansion beyond the southeastern United States.
Prospective investors
We are not currently raising. Enquiries are still welcome and are answered by the CFO’s office.
ir@baxtra.com · +1 (561) 555-0190
Existing shareholders
Quarterly shareholder letters and the annual research summary are distributed through the investor portal.
Portal accessGovernance
Board of Directors
- Margarethe Holl — Independent Chair
- Dr. Amara Osei-Boateng — Co-founder & Chief Executive Officer
- Marcus Hale — Co-founder & President, Baxtra Surgical
- Yuki Tanabe — Series B lead investor representative, chairs Audit
- Dr. Rafael Sandoval — Chairs the Science & Technology Committee
- Nadia Fahoum — Independent director, chairs Compensation
The Science & Technology Committee reviews every candidate-gate decision, including the two programs discontinued in 2026.
Policies
Code of Conduct
Applies to every employee, contractor and third party acting for Baxtra, with an anonymous, non-retaliatory speak-up line.
Anti-bribery and anti-corruption
Zero tolerance, with annual training and due diligence on every clinical and commercial third party.
Clinician payments
Payments to surgeons and physicians are at fair market value, documented, and disclosed annually under the Open Payments framework.
Political engagement
Baxtra makes no corporate political contributions.
Executive compensation
Long-term incentives are tied to pipeline and regulatory milestones, not to valuation alone.